Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 13Other hematologic neoplasm 7Thoracic 2Gynecologic 2Genitourinary 2Gastrointestinal 2Dermatologic 2CNS 2Breast 2Sarcoma 1Plasma cell 1Head & Neck 1

Conditions

Ovarian Neoplasms 16Uterine Cervical Neoplasms 8Melanoma 7Colorectal Neoplasms 7Fallopian Tube Neoplasms 6Carcinoma, Non-Small-Cell Lung 6Neoplasm Metastasis 5Breast Neoplasms 5Recurrence 4Triple Negative Breast Neoplasms 3Pancreatic Neoplasms 3Head and Neck Neoplasms 3Carcinoma, Ovarian Epithelial 3Urinary Bladder Neoplasms 2Stomach Neoplasms 2Prostatic Neoplasms 2Neoplasms 2Lymphoma 2Endometrial Neoplasms 2Carcinoma, Transitional Cell 2Carcinoma, Renal Cell 2Carcinoma, Merkel Cell 2Carcinoma, Hepatocellular 2Anus Neoplasms 2Vulvar Neoplasms 1Vulvar Diseases 1Vaginal Neoplasms 1Uterine Cervical Dysplasia 1Turcot syndrome 1Squamous Cell Carcinoma of Head and Neck 1

Interventions

pembrolizumab 5Cyclophosphamide 5Nivolumab 4Psychiatric Rehabilitation 3Paclitaxel 3Flow Cytometry 3Filgrastim 3valspodar 2sargramostim 2fludarabine 2epacadostat 2durvalumab 2atezolizumab 2aldesleukin 2Surveys and Questionnaires 2Microarray Analysis 2Methylprednisolone 2Melphalan 2Interleukin-2 2Immunologic Techniques 2Early Intervention, Educational 2Dexamethasone 2Dasatinib 2Carboplatin 2Biopsy 2Azacitidine 2Analgesia 2Amifostine 2Alemtuzumab 2vocimagene amiretrorepvec 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Lymphoma × Interleukin-2 × Gynecologic × Clear all
NCT07410494 2026-02-18

SELECT-CAR-NK

Essen Biotech

Phase 1/2 Recruiting
85 enrolled
BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicLymphoidOther hematologic neoplasmPlasma cellThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Glioblastoma, Carcinoma, Hepatocellular, Liver Neoplasms, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Melanoma, Multiple Myeloma, Neoplasm Metastasis, Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms, Leukemia, Myeloid, Acute

NCT03841110 2023-05-01

FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors

Fate Therapeutics

Phase 1 Completed
37 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidThoracic

Breast Neoplasms, Carcinoma, Renal Cell, Carcinoma, Squamous Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Lymphoma, Melanoma, Pancreatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Microsatellite Instability, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡